First Immunotherapeutic Approved for Breast Cancer
The FDA approved the immunotherapeutic atezolizumab to treat certain patients who have locally advanced or metastatic triple-negative breast cancer.
Progress Against Cancer
The FDA approved the immunotherapeutic atezolizumab to treat certain patients who have locally advanced or metastatic triple-negative breast cancer.
Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United States, it is estimated that over 40,000 women and roughly 500 men will die from...
Providing a forum for innovative cancer researchers around the world, Singapore will hold its 11th Frontiers in Cancer Science (FCS) conference from November 4-6 at Academia at SingHealth. The conference is jointly organized by the...
The women bustle around a warm, colorful kitchen, making tamales for an upcoming family party. A woman in her 20s has received the distressing news that she has tested positive for the human papillomavirus...
Since its inception in 1993, the American Association of Cancer Research (AACR) Grants Program, in partnership with other nonprofit organizations, foundations, and pharmaceutical companies, has funded groundbreaking basic, translational, and clinical cancer research. In...
The use of immunotherapy in the treatment of cancer has dramatically increased in the five years since the U.S. Food and Drug Administration (FDA) first approved the groundbreaking immunotherapeutic pembrolizumab (Keytruda). Since that September...
Pediatric cancer, while rare, is a devastating diagnosis that is estimated to affect over 11,000 children in the United States in 2019. Among those diagnosed between birth and age 14, more than 1,000 are...
As we welcome the fall season, it’s time for our September edition of Editors’ Picks, a monthly collection of articles hand-picked by the editors of the eight scientific journals published by the AACR. This...
The 12th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved wrapped up Monday in San Francisco. This year marked record attendance for the conference, as well...
In the effort to include more diverse patient populations in clinical trials, good intentions can easily go awry. Panelists in the “Addressing Advocacy at the Bench: Implementing Change” session held Sunday at The 12th...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More